Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 17.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy based on medical history and physical examination~* Serologically confirmed to be HCMV seronegative or HCMV seropositive~* Agrees to avoid unusual, unaccustomed strenuous, vigorous physical exercise/activity from 72 hours before through 72 hours after each dose of study vaccine~* Body weight ≥110 lbs (50 kg) and body mass index (BMI) of 19 to 32 kg/m\^2~* If of reproductive potential, agrees to the following during the study and for 4 weeks after the last dose of study vaccine: 1) practice abstinence from heterosexual activity, or 2) use or have their partner use 2 allowable methods of birth control during heterosexual activity~Exclusion Criteria:~* Has previously received any cytomegalovirus vaccine~* Has history of allergic reaction or anaphylactic reaction to any vaccine component that required medical intervention~* Has history of any severe allergic reaction that required medical intervention~* Is pregnant or breastfeeding or expecting to conceive from 2 weeks before the study through 1 month after the last dose of study vaccine~* Plans to donate eggs or sperm from study start through 1 month after the last dose of study drug~* Has impairment of immunologic function including, but not limited to autoimmune disease, splenectomy, or human immunodeficiency virus acquired immunodeficiency syndrome (HIV/AIDS)~* Received systemic corticosteroids for ≥14 consecutive days and has not completed treatment within 30 days of study start~* Received immunosuppressive therapy including, but not limited to rapamycin and equivalents, tacrolimus, FK-506, fujimycin, or other therapies used for solid organ/cell transplant, radiation therapy, immunosuppressive/cytotoxic chemotherapy, or other therapy known to interfere with the immune response within 1 year of study start~* Has a condition in which repeated venipuncture or injections pose more than minimal risk, such as hemophilia, thrombocytopenia or other severe coagulation disorders, or significantly impaired venous access~* Has a condition that requires active medical intervention or monitoring such as diabetes mellitus, autoimmune disease, or a clinically significant chronic medical condition that is considered progressive~* Has history within the past 5 years or current drug or alcohol abuse~* Has major psychiatric illness~* Is legally or mentally incapacitated~* Has participated in another clinical study in the past 4 weeks, or plans during the present study to participate in a treatment-based study or a study in which an invasive procedure is performed~* Has received valganciclovir, ganciclovir, valacyclovir, foscarnet, or cidofovir from 4 weeks prior to 1 month following each V160 vaccination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HCMV seropositive (+) V160 Low Dose Intramuscular (IM) (Type: EXPERIMENTAL): Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
- HCMV seronegative (-) V160 Low Dose IM (Type: EXPERIMENTAL): Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
- HCMV+ V160 Medium Dose IM (Type: EXPERIMENTAL): Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
- HCMV- V160 Medium Dose IM (Type: EXPERIMENTAL): Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
- HCMV+ V160 High Dose IM (Type: EXPERIMENTAL): Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
- HCMV- V160 Medium Dose plus MAPA 225 µg IM (Type: EXPERIMENTAL): Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
- HCMV- V160 High Dose IM (Type: EXPERIMENTAL): Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
- HCMV+ V160 High Dose plus MAPA 225 µg IM (Type: EXPERIMENTAL): Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
- HCMV+ V160 Maximum Dose IM (Type: EXPERIMENTAL): Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
- HCMV- V160 High Dose plus MAPA 225 µg IM (Type: EXPERIMENTAL): Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
- HCMV- V160 Maximum Dose IM (Type: EXPERIMENTAL): Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
- HCMV+ Placebo IM (Type: PLACEBO_COMPARATOR): Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
- HCMV- Placebo IM (Type: PLACEBO_COMPARATOR): Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
- HCMV+ V160 Medium Dose Intradermal (ID) (Type: EXPERIMENTAL): Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
- HCMV- V160 Medium Dose ID (Type: EXPERIMENTAL): Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
- HCMV+ Placebo ID (Type: PLACEBO_COMPARATOR): Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
- HCMV- Placebo ID (Type: PLACEBO_COMPARATOR): Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete